Circulation
FEBRUARY 25, 2024
Circulation, Volume 149, Issue 9 , Page 707-716, February 27, 2024. RNA therapeutics hold significant promise in the treatment of cardiovascular diseases. RNAs are biologically diverse and functionally specific and can be used for gain- or loss-of-function purposes. The effectiveness of mRNA-based vaccines in the recent COVID-19 pandemic has undoubtedly proven the benefits of an RNA-based approach.
Heart Sisters
FEBRUARY 25, 2024
Could our healthcare professionals learn from the “Great Explainer” how to communicate jargon-free information to patients?
Frontiers in Cardiovascular Medicine
FEBRUARY 25, 2024
Background Discordance between coronary angiographic findings and invasive functional significance is well-established. Yet, the prevalence of this mismatch in an era increasingly utilizing invasive functional assessments, such as fractional flow reserve (FFR), remains unclear. This study examines the extent of such discrepancies in current clinical practice.
CardiacWire
FEBRUARY 25, 2024
Philips made interventional imaging headlines last week, announcing the US and European launch of its LumiGuide interventional imaging system, positioning it as a key step toward “bringing healthcare closer to entirely radiation-free surgery.” Powered by Philips’ Fiber Optic RealShape (FORS) technology and exclusively compatible with Philips interventional systems, LumiGuide uses light reflected along an optical fiber inside a guidewire to generate 3D, high-resolution, color images of interventi
Frontiers in Cardiovascular Medicine
FEBRUARY 25, 2024
Background Arteriovenous (AV) grafts often develop severe complications of stenosis due to neointimal proliferation that occurs either at the venous anastomosis site or at the outflow receiving vein. This study compares primary patency during 12 months of follow up for a new experimental Biomodics © interpenetrating polymer network (IPN) drug-eluting graft prototype with state-of-the-art GORE® ACUSEAL (ACUSEAL) in an AV graft model in sheep.
HCPLive
FEBRUARY 25, 2024
Robert Wood, MD, principal investigator of the OUtMATCH trial, offers insight into the trial and its results beyond the primary outcome, with a focus on what it means for patients and providers.
Frontiers in Cardiovascular Medicine
FEBRUARY 25, 2024
Introduction Many factors contribute to the risk of cardiovascular disease (CVD), an umbrella term for several different heart diseases, including inflammation. Macrophage migration inhibitory factor (MIF) is an important immune modulator that has been shown to be involved in the pathogenesis of different heart diseases, so understanding pathogenic variants of the MIF gene is important for risk stratification.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
Frontiers in Cardiovascular Medicine
FEBRUARY 25, 2024
Background There are different types of transcatheter mitral valve repair (TMVr) currently in clinical use, including leaflet approximation, annular cinching, and restoration of the chordal apparatus of the mitral valve (MV). While the concomitant combination (COMBO) therapy of mitral transcatheter edge-to-edge repair (M-TEER) with another TMVr concept has been proven feasible, potentially offering patient-tailored treatment for severe mitral regurgitation (MR), a comparison with M-TEER alone ha
Journal of Cardiothoracic Surgery
FEBRUARY 25, 2024
Artificial intelligence (AI) is a transformative technology with many benefits, but also risks when applied to healthcare and cardiac surgery in particular. Surgeons must be aware of AI and its application thr.
All About Cardiovascular System and Disorders
FEBRUARY 25, 2024
Left ventricular noncompaction is an incidental echocardiographic finding in some while others may be symptomatic. In left ventricular noncompaction, there is a thin subepicardial compact layer and a thick subendocardial layer which is non-compact and has prominent trabeculations and recesses between the trabeculae. Blood flow into and out of these recesses can provide a spectacular view on colour Doppler echocardiography, almost looking like flames of fire near the apex, in the apical four cham
Journal of Cardiothoracic Surgery
FEBRUARY 25, 2024
Broncho-esophageal fistula (BEF) secondary to esophageal diverticulum is a rare clinical condition, which is often misdiagnosed for a long time. The aim of our study is to summarize and clarify the advantages.
HCPLive
FEBRUARY 25, 2024
Omalizumab, the only FDA-approved treatment for multiple food allergies, demonstrated significant efficacy in the OUtMATCH trial, with 67% achieving the primary outcome compared to 7% in the placebo group.
The American Journal of Cardiology
FEBRUARY 25, 2024
Publication date: Available online 24 February 2024 Source: The American Journal of Cardiology Author(s): Yousaf Abughofah, Wesley Anderson, Rolf P Kreutz
Circulation
FEBRUARY 25, 2024
Circulation, Volume 149, Issue 9 , Page 722-724, February 27, 2024.
HCPLive
FEBRUARY 25, 2024
In this interview, Ebisawa discusses his team’s recent research into the frequently-discussed non-injector epinephrine alternative neffy.
Circulation
FEBRUARY 25, 2024
Circulation, Volume 149, Issue 9 , Page 639-640, February 27, 2024.
HCPLive
FEBRUARY 25, 2024
More than half of older patients admitted to geriatric units in France had iron deficiency, including patients without anemia.
HeartRhythm
FEBRUARY 25, 2024
Remote monitoring (RM) is recommended to follow patients with implantable cardioverter defibrillators (ICDs).1 RM enables early detection of critical conditions and reduces in-clinic evaluations. However, adoption lags. An acknowledged barrier is insufficient personnel, linked to insufficient reimbursement, to conduct the “invisible” clinic work associated with virtual care (e.g., triaging alerts, documentation, patient communication and scheduling).2 This encourages a re-examination of the RM s
The American Journal of Cardiology
FEBRUARY 25, 2024
Publication date: Available online 25 February 2024 Source: The American Journal of Cardiology Author(s): Mihail Celeski, Andrea Segreti, Dajana Polito, Daniele Valente, Luisa Vicchio, Giuseppe Di Gioia, Gian Paolo Ussia, Raffaele Antonelli Incalzi, Francesco Grigioni
HeartRhythm
FEBRUARY 25, 2024
Loading oral sotalol for atrial fibrillation (AF) requires 3 days, frequently in-hospital, to achieve steady state. The FDA approved loading with intravenous (IV) sotalol through model-informed development, without patient data.
The American Journal of Cardiology
FEBRUARY 25, 2024
Publication date: Available online 25 February 2024 Source: The American Journal of Cardiology Author(s): Ethan Sacoransky, Danny Yu Jia Ke, Bryce Alexander, Wael Abuzeid
Circulation
FEBRUARY 25, 2024
Circulation, Volume 149, Issue 9 , Page 656-657, February 27, 2024.
The American Journal of Cardiology
FEBRUARY 25, 2024
Publication date: Available online 25 February 2024 Source: The American Journal of Cardiology Author(s): Wissam Mekary, Faisal M.
Circulation
FEBRUARY 25, 2024
Circulation, Volume 149, Issue 9 , Page 725-726, February 27, 2024.
Circulation
FEBRUARY 25, 2024
Circulation, Volume 149, Issue 9 , Page e936-e936, February 27, 2024.
Circulation
FEBRUARY 25, 2024
Circulation, Volume 149, Issue 9 , Page 727-728, February 27, 2024.
Circulation
FEBRUARY 25, 2024
Circulation, Volume 149, Issue 9 , Page 641-643, February 27, 2024.
Circulation
FEBRUARY 25, 2024
Circulation, Volume 149, Issue 9 , Page 717-721, February 27, 2024.
Expert insights. Personalized for you.
102 
Let's personalize your content